NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02395640,The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer,https://clinicaltrials.gov/study/NCT02395640,,COMPLETED,This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.,NO,Gastric Cancer,DRUG: Epirubicin|DRUG: Oxaliplatin|DRUG: Capecitabine,"progression free survival, 7 months","overall survival, 10 months|overall response rate, 2 months|Number of Participants with Adverse Events, 2 months|quality of life questionnaire, 2 months",,Fudan University,,ALL,"ADULT, OLDER_ADULT",PHASE3,438,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,FDZL-EXELOX,2015-03,2021-02-23,2021-02-23,2015-03-23,,2021-10-26,"Fudan University Cancer Hospital, ShangHai, Shanghai, 200032, China",
